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Introduction
Natural cell-mediated cytotoxicity is a major innate cel-
lular defence mechanism against infection and cancer,
and cell mediating natural killing (NK) and natural cyto-
toxicity (NC) are crucial elements of it [1]. The major
differences between NK and NC are the receptors and
mechanism involved in cytotoxicity [2–4]. The initial
step in the mechanism of NK and NC is recognition and
binding of effector cells to tumour cells via receptor–
ligand interactions [5]. Cell-mediating NK were tradi-
tionally defined as cells that lyse lymphoid targets such
as YAC-1 in short-term in vitro cytotoxicity assays [6],
whilst cells-mediating NC were first characterized as cells
that lyses non-lymphoid fibrosarcomas in long-term cyto-
toxicity assays [7]. NK-cell responses are mediated
through cell-surface receptors that can either be inhibi-
tory or activating.
An anti-tumour surveillance role for NC was origi-
nally proposed on the basis that spleen cells could medi-
ate in vitro lytic activity against 3-MCA-induced
fibrosarcomas [1, 5]. NK cells express a variety of activat-
ing and inhibitory receptors that use opposing signalling
motifs to stimulate or inhibit activation [4]. These recep-
tors induce signals, which the balance of these signals
forms the decision of whether an NK cell becomes acti-
vated or activation is inhibited. This recognition system
has some degree of flexibility, which means that NK cells
use several strategies that allow their receptors to recog-
nize diverse ligands. Although unlike T and B cells, flex-
ibility is not achieved through the rearrangement of gene
clusters, but NK-cell recognition receptor families have
achieved flexibility through rapid genetic evolution
(within a species) and reported promiscuity of ligand
binding [4, 8, 9].
Cytotoxicity receptors (NCRs) are a group of activat-
ing receptors, which belong to the Ig superfamily [8].
The appearance of these receptors specifically NKp44
illustrated the rapid nature of the evolution of NK-cell
receptors [10]. In humans, NCRs NKp46, NKp80 and
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Abstract
We have previously reported a new receptor (NC-2) for natural cytotoxicity
(NC) on murine leucocytes, identified by monoclonal antibody D9 (mAb D9).
Pretreatment of mouse spleen cells with different concentrations of mAb D9
in vitro blocked NC against WEHI-164, whereas natural killing (NK) activity
against YAC-1 was unaffected. This paper reports the immune surveillance
against the growth of WEHI-164 tumour cells in mice by NC-2+ Cells. The
kinetics of in vivo reduction in NC activity were investigated by treating
BALB ⁄ c and (CBA · C57BL ⁄6) F1 mice with a single injection of 40 lg of
mAb D9 and monitoring splenic NC activity by 51Cr-release assay at intervals
from 24 h to 3 weeks. Control mice were injected with OKT8 irrelevant anti-
body. Results showed a significant (P < 0.05) reduction in splenic NC activity
within 24 h which persisted for up to 1 week. Similar results were also
obtained when (CBA · C57BL ⁄6) F1 mice were employed (P < 0.001). In vivo
tumour studies were undertaken to investigate the role of NC-2+ cells in sur-
veillance against tumour growth and metastasis of the WEHI-164 fibrosar-
coma. When syngeneic BALB ⁄ c mice were injected with 40 lg of mAb D9
and then challenged with 5 · 105 WEHI-164 cells, results showed signifi-
cantly increased growth rate of the transplanted WEHI-164 fibrosarcoma and
tumour nodules in the lungs of animals, when compared to control mice with
normal NC activity. Our data support an innate surveillance in metastasis and
growth of WEHI-164 fibrosarcoma in mice.
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NKp30 are expressed on activated and resting NK cells,
but NKp44 is upregulated following interleukin-2 stim-
ulation of some NK cells [11, 12]. Cellular ligands may
exist, given that anti-NCR antibodies abrogate NK-cell-
mediated lysis of many tumour cell types [13–17].
The NCRs are receptors triggering NK cells upon
ligation to tumour targets [13, 16]. This is supported by
studies showing that deletion of a single NCR reduces
the ability of NK cells to lyse tumour targets in vivo [16,
18, 19]. These NCRs receptors are important in the use
of NK cells in cancer therapy.
To our knowledge, only two receptors, NC-1.1 [20]
and NC-2 [21], have been identified on murine leuco-
cytes, which mediate NC against WEHI-164 (NC-sensi-
tive target) whilst the activity of these cells against
NK-sensitive target (YAC-1 tumour cells) was not
affected. Studies showed that mice rendered deficient in
NC by the administration of the anti-NC-1.1 mAb 1C4
have accelerated growth of a number of transplantable
tumours [22] and exhibited increased susceptibility to
chemical carcinogens [23] compared to control mice.
These results provide the first direct evidence that in
mice at least, NC has a role in tumour surveillance.
We have previously reported the production and char-
acterization of an anti-NC mAb D9 that identifies the
NC-2 receptor on cells mediating NC. NC-2 is a differ-
ent receptor to NC-1.1. In vitro blocking studies showed
that pretreatment of (CBA · C57BL ⁄6) F1 mouse spleen
cells with mAb D9 blocked NC against WEHI-164,
whereas NK activity against YAC-1 (NK target) was
unaffected. Furthermore, we have shown that mAbD9
blocked effector cells-WEHI-164 tumour cell conjugation
approximately 50%, whilst conjugation to YAC-1
tumour cells was not affected [21]. We predicted from
the in vitro data that mAb D9, like mAb 1C4, would
reduce splenic NC when administered into mice. There-
fore, an NC-deficient mouse model was generated to
study the NC-2 tumour surveillance in vivo.
This paper reports the ability of mAb D9 (anti-NC-2)
to deplete splenic NC in vivo and the use of these NC-
deficient mice to study the growth and metastasis of the
3-MCA-induced WEHI-164 fibrosarcoma.
Materials and methods
Tissue culture medium (TCM). Dulbecco’s modification
of Eagle’s medium (CSL, Melbourne, Vic., Australia)
was supplemented with 20 mM 4-(2-hydroxyethyl)-1
piperazineethanesulfonic acid, 2 mM L-glutamine, 50 lM 2-
mercaptoethanol 0.15% sodium bicarbonate, 50 lg ⁄ml
gentamicin and 10% foetal calf serum.
Animals. BALB ⁄ c and (CBA · C57BL ⁄6) F1 mice of
both sexes were selected according to our previous finding
about the cytotoxicity of splenic leucocytes from different
inbred mouse strains. The above-mentioned mice had
higher NC activity against WEHI-164 tumour cells [21].
The animals were maintained in David Maddison Clinical
Sciences Building Animal Facility under standard condi-
tions and used between 10 and 12 weeks of age.
Cytotoxicity assay. Splenic NC activity was assayed by
in vitro lysis of 51Cr-labelled WEHI-164, as previously
described [21]. The experiment was conducted in quadru-
plicate in 200 ll TCM in 96-well microtiter trays.
Briefly, spleen cells were incubated with 51Cr-labelled
targets at effector ⁄ target (E:T) ratios in the range of
100:1–12.5:1. The cells were pelleted at 150 g for 1 min
and incubated at 37C ⁄5% CO2 for 18 h. Supernatants
(100 ll) from each well were harvested and the level of
radioactivity measured in a COBRA gamma-counter
(Packard Instrument CO., Downer’s Grove, IL, USA). The
results were first calculated as percentage specific lysis:
Percentage specific lysis
¼ Test c.p.m Background c.p.m
Total release c.p.m Background c.p.m 100
Background count per million (c.p.m) was obtained
from wells containing target cells alone and total release
was determined by counting 51Cr-labelled target cells.
Time– and dose–response studies. To determine the dose–
response effect of mAb D9 on BALB ⁄ c splenic NC activ-
ity, mice were injected intraperitoneally (i.p.) with 5, 10,
20, 40, 80 or 160 lg of mAb D9. Control mice were
injected with equivalent doses of OKT8 (IgG2a), an iso-
type matched mAb. Twenty-four hours later, splenic NC
activity of each mouse was assayed in vitro against 51Cr-
labelled WEHI-164 target. (CBA · C57BL ⁄6) F1 mice
were similarly tested for the effect of mAb D9 treatment
in vivo. The minimal dose of mAb D9 required to achieve
maximal reduction in splenic NC activity was 40 lg for
both strains of mice; therefore, this dose was used
throughout the study.
A time–response study for mAb D9 was carried out in
BALB ⁄ c mice (n = 20) that were injected i.p. with 40 lg
of mAb D9. At different times (24 h, 72 h, 1 week,
2 weeks and 3 weeks) after injection, five mice from each
group were killed and their spleens were individually
tested in 51Cr-release assays against WEHI-164 targets.
A similar experiment was carried out in (CBA ·
C57BL ⁄6) F1 mice.
In vivo tumour growth studies. The MTD100 dose of
WEHI-164 fibrosarcoma (a 3-methylclontren-induced
BALB ⁄ c fibrosarcoma) was determined by subcutaneously
injecting 5 · 105, 1 · 106 or 5 · 106 tumour cells into
the chest of three groups (n = 10) of BALB ⁄ c mice. The
animals were monitored for tumour growth every 2 days
for up to 10 days after tumour cell inoculation. Results
showed that all mice given a dose of 5 · 105 WEHI-164
cells grew tumours within 4 days, and this was the
MTD100 dose used in subsequent experiment. To test the
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effects of mAb D9 on WEHI-164 tumour growth in vivo,
two groups (n = 25) of BALB ⁄ c mice were used. Group 1
mice were i.p. injected with 40-lg affinity-purified mAb
D9 in 200 ll of TCM. Group 2 mice were injected with
a similar dose of OKT8 isotype-matched antibody. Mono-
clonal antibody treatments were carried out on days )2,
0, 2, 7 and 14 and 5 · 105 WEHI-164 cells were inocu-
lated on day 0. The mice were monitored every 2 days
and the tumours were measured as two diameters at right
angles. The results are presented as mean tumour area
(mm2) ±SE according to the following formula [24].
Mean tumour area ¼ p Diameter 1þDiameter 2
4
 2
Tumour metastasis studies. The ability of WEHI-164
tumour cells to metastasis to the lungs was examined in
this study. The minimal dose of cells to give 10–20 lung
nodules in BALB ⁄ c mice was determined by intravenously
(iv) injecting graded numbers (5 · 103, 1 · 104, 1 · 105
or 5 · 105) of WEHI-164 cells into the tail veins of
groups (n = 8) of anaesthetized [15 mg ⁄kg Rompun
(Bayer, Sydney, Australia) and 100 mg ⁄kg Ketamine
(Parnell Laboratories, Alexandria, Australia) per mouse]
BALB ⁄ c mice. The mice were killed on days 7, 10, 12
and 14 and the lungs were carefully removed, given a
gentle rinse in saline and fixed in Bouin’s solution (75 ml
picric acid, 25 ml 40% formaldehyde and 5 ml glacial
acetic acid). The number of lung tumour nodules was
counted using a dissecting microscope. The regimen
selected to study the effects of mAb D9 on tumour
metastasis was i.v. injection of 1 · 105 WEHI-164 cells
per mouse and harvesting the lungs 2 weeks later.
In this experiment, three groups (10 mice in each
group) of mice were injected i.p. with 200 ll PBS con-
taining 40 lg of mAb D9 or PBS alone as control, on
days )2, 0, 2 and 7. On day 0, 1 · 105 WEHI-164
tumour cells were injected into the tail veins of anaesthe-
tized mice. Two weeks after tumour cell inoculation, the
mice were sacrificed and their lungs were removed and
fixed in Bouin’s solution. In this experiment, the tumour
nodules in the lungs of the antibody-treated mice were
too extensive to be counted, and hence, the lungs were
weighed and the mean lung weights were compared
amongst the three groups of mice.
Statistical analysis. The obtained data were reported as
mean ± SEM. Student’s t test or Mann–Whitney U test
was used to determine statistical significance between test
and control groups. A P-value of <0.05 was considered
significant.
Results
The kinetics of in vivo reduction in NC activity was
investigated by treating BALB ⁄ c and (CBA ·
C57BL ⁄6) F1 mice. The animals were injected (i.p.)
40 lg of mAb D9. At different times (24 h, 72 h,
1 week, 2 weeks and 3 weeks) after mAb injection, five
mice of each group were killed and their spleen cells
were individually tested in 51Cr release assay against
WEHI-164 targets. Control mice were injected with
OKT8 irrelevant antibody. Results for BALB ⁄ c mice are
shown in (Fig. 1). A significant (P < 0.05) reduction in
splenic NC activity was evident within 24 h which per-
sisted for up to 1 week. The experiment was repeated in
(CBA · C57BL ⁄6) F1 mice with similar results (Fig. 2).
The reduction in NC activity at 24 h was highly signifi-
cant (P < 0.001) compared to control mice.
Role of NC-2+ cells on the local growth of the WEHI-164
fibrosarcoma in BALB ⁄ c mice
Results of the experiment that examined the effects of a
reduction in NC activity by mAb D9 (anti–NC-2) on
the growth of the WEHI-164 fibrosarcoma are shown in
Fig. 3. Between days 6 and 10 when the tumour area
was <85 mm2, mAb D9-treated mice consistently
showed significantly increased growth of the tumour
compared to control mice treated with the isotype-
matched antibody (P < 0.05, Mann–Whitney U test).
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Figure 1 In vivo time–response study of a single dose of mAb D9 on
splenic natural cytotoxicity (NC) of BALB ⁄ c mice (n = 20) measured
in vitro. Mice were injected (i.p.) 40 lg of mAb D9. At different times
(24 h, 72 h, 1 week, 2 weeks and 3 weeks) after mAb injection, five
mice of each group were killed and their spleens were individually
tested in 51Cr release assay against WEHI-164 targets. Results showed
a significant reduction in splenic NC activity within 24 h and persisted
for up to 1 week (*P < 0.05, student’s t test).
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The difference in tumour growth was evident from as
early as day 4 although the results did not reach statisti-
cal significance.
Role of NC-2+ cells on lung metastasis of WEHI-164
fibrosarcoma in BALB ⁄ c mice
Results of the experiment that examined the effects of
mAb D9 on WEHI-164 metastasis showed significantly
increased lung weights in the anti–NC-2 mAb-treated
group when compared to control mice (the mice treated
with tumour cells and PBS alone). Two weeks after
WEHI-164 cell inoculation, the lungs of the mAb D9-
treated group weighed between 0.243 and 0.940 g
(mean = 0.543 ± 0.055) compared to the lung weights
of the control group, which were between 0.175 and
0.385 g (mean = 0.268 ± 0.023) (P < 0.002). Number
of tumour nodules in the lungs of the mAb D9-treated
group was more than 100 and could not be counted. In
contrast, the lungs of the control mice showed between
10 and 60 nodules (Fig. 4).
Discussion
Injection of a single dose of mAb D9 into mice depleted
splenic NC activity within 24 h and the effect persisted
for up to 1 week in a dose-dependent manner. In vivo
tumour studies were undertaken to investigate the role of
NC-2+ cells in surveillance against tumour growth and
metastasis of the WEHI-164 fibrosarcoma. When synge-
neic BALB ⁄ c mice were injected with mAb D9 and then
challenged subcutaneously with WEHI-164, results
showed significantly increased growth rate of the trans-
planted WEHI-164 fibrosarcoma when compared to con-
trol mice with normal NC activity.
As reported previously [21], incubation of spleen cells
from a number of inbred mouse strains, BALB ⁄ c,
C57BL ⁄6, CBA and (CBA · C57BL ⁄6) F1, with mAb
D9 (anti-NC-2) reduced splenic NC activity against the
NC-sensitive WEHI-164 target by approximately 50%,
but NK activity against the NK-sensitive YAC-1 target
in vitro was not affected [21]. BALB ⁄ c and (CBA ·
C57BL ⁄6) F1 mice were selected according to our previ-
ous finding about the cytotoxicity of splenic leucocytes
from different inbred mouse strains. The above-men-
tioned mouse strains had higher NC activity against
WEHI-164 tumour cells. The cytotoxicity of (CBA ·
C57BL ⁄6) F1 mice was more than other mouse strains,
even more than BALB ⁄ c mice. This could explain why
F1-mice Cr release assay results show a twice as efficient
killing of target cells when compared to BALB ⁄ c mice.
The in vitro treatment also blocked effector spleen
cell–WEHI-164 target cell conjugation by a similar
amount. Further cellular, functional and biochemical data
50
40
30
20
10
0
0 20 40 60
Effector:Target ratio
Pe
rc
en
ta
ge
 sp
ec
ifi
c 
ly
sis
80 100 120
Control
*
*
**
24 h
72 h
144 h
240 h
Figure 2 In vivo time–response study of a single dose of mAb D9 on
splenic natural cytotoxicity (NC) of (CBA · C57BL ⁄ 6) F1 mice
(n = 20) measured in vitro. Mice were injected (i.p.) 40 lg of mAb D9.
At different times (24 h, 72 h, 1 week, 2 weeks and 3 weeks) after
mAb injection, five mice of each group were killed and their spleens
were individually tested in 51Cr release assay against WEHI-164 targets.
Results showed a significant reduction in splenic NC activity at 24 h,
72 h and 1 week (**P < 0.001, *P < 0.05, students, t test).
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Figure 3 Effect of mAb D9 treatment on the growth of WEHI-164
fibrosarcoma in BALB ⁄ c mice. Between days 6 and 10 when the tumour
area was <85 mm2, mAb D9-treated mice consistently showed increased
tumour growth compared to control mice treated with the isotype
matched antibody. Results are presented as mean tumour area (mm2)
±SE for groups of 25 mice (*P < 0.05, Mann–Whitney U test). The
figure is the representative of two repeated experiments.
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indicated that NC-2 is not the same receptor as the NC-
1.1 receptor identified by moAb 1C4 on cells mediating
NC.
Mice rendered NC deficient by injection of mAb 1C4
showed reduced tumour surveillance when compared to
control mice [20, 22]. The in vitro data obtained for mAb
D9 suggested that its injection into mice in vivo would
also deplete splenic NC.
When WEHI-164 was intravenously transferred into
BALB ⁄ c mice, a profound increase in metastatic lung
nodules was observed in mice injected with mAb D9.
The difference in lung weight was up to seven times
greater in the mAb D9-treated mice than in the control
mice, indicating a significant increase in metastasis. This
is the first direct report that NC has a role in surveillance
against metastasis and that this activity is mediated by
both NC-2+ cells.
The ability of NK cells in immune surveillance
against cancer has extensively been reviewed by Wald-
hauer and Steinle [25]. NK cells exert their effector func-
tions via exocytosis of perforin-containing cytolytic
granules to directly kill target cells and the release of
proinflammatory cytokines. The most important cyto-
kines are interferon gamma (IFN-c) and tumour necrosis
factor. The activity of NK cells is mediated by a complex
interaction between various inhibitory and activating
receptors [26–29] signalling pathways initiated after
cross-linking of the activating receptors resulting in the
distinct effector functions are just beginning to be
cleared.
A recent investigation showed that malignant cells
express a set of ligands that mediate NK-cells recogni-
tion. These ligands are shared amongst murine cell lines,
murine primary melanomas and human metastasis. These
ligands recognition by NK-cell-activating receptors
(NCRs and DNAM-1) mediates melanoma cell killing
[30].
Experimental evidence was derived from a number of
studies which showed that suppression of NK in mice
resulted in an increased incidence of lung metastatic nod-
ules [31]. It has been reported that allogeneic blood
transfusion that reduced pulmonary NK also increased
lung metastasis of an UV-2237 fibrosarcoma in syngenic
mice, and this immunological surveillance was not
because of T cells [32].
In conclusion, our data supports an innate surveillance
in metastasis, at least of a chemically induced fibrosar-
coma. It is possible that enhancement of NC by immuno-
modulatory drugs such as levamisole [33] could
control the haematogenous spread of certain metastatic
tumours.
It is not known whether mAb D9 blocks the NC-2
receptor after in vivo treatment or depletes a cell popula-
tion that is mediating NC. This should be performed by
immunophenotyping of spleen cells from D9-treated
mice. Further study of the NC-2 receptor is also needed
to characterize better the specificity of D9 antibody
including information on different cell populations, the
consequences of D9-injection on numbers of cytotoxic
cell-population and cellular distribution in the spleens of
mice. Multicolour flow cytometry to define the cell popu-
lation that expresses the NC-2 receptor and co-staining
with different markers of NK cells and other leuco-
cyte ⁄ lymphocyte markers are also suggest.
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